Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes

被引:127
|
作者
Liddle, C [1 ]
Goodwin, BJ
George, J
Tapner, M
Farrell, GC
机构
[1] Univ Sydney, Dept Clin Pharmacol, Westmead Hosp, Storr Liver Unit, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Hosp, Dept Med, Westmead, NSW 2145, Australia
来源
关键词
D O I
10.1210/jc.83.7.2411
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CYP3A4, the predominant cytochrome P450 expressed in human liver, is responsible for the metabolism of endogenous steroids and many drugs. On the basis of pharmacokinetic studies in patients with hormonal derangements and the effects of replacement therapy, it has been suggested that iodothyronines decrease CYP3A4-mediated drug metabolism, whereas glucocorticoids and GH enhance CYP3A4 activity. The aim of the present study, using well differentiated human hepatocytes in primary culture, was to examine directly whether hormonal factors regulate CYP3A4 gene expression. Addition of T-3 to primary hepatocytes resulted in a marked reduction of CYP3A4-catalyzed testosterone GP-hydroxylase activity and corresponding levels of CYP3A4 protein and messenger ribonucleic acid compared to those in untreated cells. Conversely, both dexamethasone and GH treatment substantially increased CYP3A4 gene expression. None of the hormones studied consistently altered the expression of other human cytochrome P450 genes. We conclude that iodothyronines, glucocorticoids, and GH act directly on human hepatocytes to regulate the expression of CYP3A4, and these effects appear to be exerted at a pretranslational level. Altered regulation of hepatic CYP3A4 is, therefore, likely to account for previous observations concerning the effects of endocrine diseases and hormonal treatments on human cytochrome P450-mediated drug and steroid metabolism.
引用
收藏
页码:2411 / 2416
页数:6
相关论文
共 50 条
  • [41] Structural features of midazolam allostery by cytochrome P450 3A4
    Roberts, Arthur G.
    DRUG METABOLISM REVIEWS, 2011, 43 : 70 - 70
  • [42] Rate limiting steps in cytochrome P450 3A4 catalysis
    Krauser, JA
    Guengerich, FP
    FASEB JOURNAL, 2004, 18 (08): : C238 - C238
  • [43] Taurine modulates catalytic activity of cytochrome P450 3A4
    V. V. Shumyantseva
    A. A. Makhova
    T. V. Bulko
    R. Bernhardt
    A. V. Kuzikov
    E. V. Shich
    V. G. Kukes
    A. I. Archakov
    Biochemistry (Moscow), 2015, 80 : 366 - 373
  • [44] Cytochrome P450 3A4 drug interaction profile of tofacitinib
    Krishnaswami, Sriram
    Lamba, Manisha
    Gupta, Pankaj
    Takiya, Liza
    Wang, Ronnie
    Kaplan, Irina
    Salageanu, Joanne
    Tarabar, Sanela
    Alvey, Christine
    Ndongo, Marie-Noella
    PHARMACOTHERAPY, 2012, 32 (10): : E240 - E240
  • [45] Regioselectivity preference of testosterone hydroxylation by cytochrome P450 3A4
    Zhang, Yan
    Morisetti, Phani
    Kim, Jeffery
    Smith, Lynelle
    Lin, Hai
    THEORETICAL CHEMISTRY ACCOUNTS, 2008, 121 (5-6) : 313 - 319
  • [46] Peripheral Ligand Binding and Allostery in Cytochrome P450 3A4
    Davydov, Dmitri R.
    Rumfeldt, Jessica A. O.
    Sineva, Elena V.
    Davydova, Nadezhda Y.
    Halpert, James R.
    FASEB JOURNAL, 2012, 26
  • [47] Involvement of human cytochrome P450 3A4 in the metabolism of vamidothion
    Mehmood, Z
    Kelly, DE
    Kelly, SL
    PESTICIDE SCIENCE, 1996, 46 (03): : 287 - 290
  • [48] Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole
    Wen, B
    Gartner, CA
    Cameron, MD
    Nelson, SD
    DRUG METABOLISM REVIEWS, 2003, 35 : 101 - 101
  • [49] Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
    Gruer, PJK
    Vega, JM
    Mercuri, MF
    Dobrinska, MR
    Tobert, JA
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (07): : 811 - 815
  • [50] Structural basis for ligand promiscuity in cytochrome P450 3A4
    Ekroos, Marika
    Sjogren, Tove
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (37) : 13682 - 13687